drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate
drug_description
An antibody–drug conjugate where a trastuzumab-based anti-HER2 antibody targets HER2-expressing tumor cells and delivers a deruxtecan (DXd) topoisomerase I inhibitor payload, causing DNA damage and apoptosis; the membrane-permeable payload enables a bystander effect and the Fc region may mediate ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
A trastuzumab-based anti-HER2 antibody binds HER2 on tumor cells, is internalized, and releases the deruxtecan (DXd) payload, a membrane-permeable topoisomerase I inhibitor that induces DNA damage and apoptosis; the payload can exert a bystander effect on neighboring cells, and the antibody Fc region may mediate ADCC.
drug_name
Trastuzumab deruxtecan (T-DXd, DS-8201a)
nct_id_drug_ref
NCT06174987